These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 25030213)
1. Individualized prostate-specific antigen threshold values to avoid overdiagnosis of prostate cancer and reduce unnecessary biopsy in elderly men. Kanao K; Komori O; Nakashima J; Ohigashi T; Kikuchi E; Miyajima A; Nakagawa K; Eguchi S; Oya M Jpn J Clin Oncol; 2014 Sep; 44(9):852-9. PubMed ID: 25030213 [TBL] [Abstract][Full Text] [Related]
2. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml. Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854 [TBL] [Abstract][Full Text] [Related]
3. Prostate specific antigen density of the transition zone for early detection of prostate cancer. Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889 [TBL] [Abstract][Full Text] [Related]
4. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans. Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990 [TBL] [Abstract][Full Text] [Related]
5. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892 [TBL] [Abstract][Full Text] [Related]
6. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843 [TBL] [Abstract][Full Text] [Related]
7. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492 [TBL] [Abstract][Full Text] [Related]
8. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484 [TBL] [Abstract][Full Text] [Related]
9. Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection. Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y Int J Urol; 2005 Oct; 12(10):881-5. PubMed ID: 16323981 [TBL] [Abstract][Full Text] [Related]
10. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698 [TBL] [Abstract][Full Text] [Related]
11. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL. Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929 [TBL] [Abstract][Full Text] [Related]
12. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range. Haese A; Dworschack RT; Partin AW J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298 [TBL] [Abstract][Full Text] [Related]
13. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502 [TBL] [Abstract][Full Text] [Related]
14. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169 [TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases. Kang SH; Bae JH; Park HS; Yoon DK; Moon DG; Kim JJ; Cheon J Int J Urol; 2006 Jul; 13(7):910-4. PubMed ID: 16882054 [TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of free PSA in early detection of prostate cancer. Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H; Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278 [TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening in Tyrol, Austria: experience and results. Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519 [TBL] [Abstract][Full Text] [Related]
18. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037 [TBL] [Abstract][Full Text] [Related]
19. [Usefulness and predictive value of PSA density, adjusted by transition zone volume, in men with PSA levels between 2 and 4 ng/ml]. Janane A; Hajji F; Ismail T; Jawad C; Elondo JC; Dakka Y; Ghadouane M; Ameur A; Abbar M; Albouzidi A Actas Urol Esp; 2012 Feb; 36(2):93-8. PubMed ID: 22188752 [TBL] [Abstract][Full Text] [Related]
20. Developing a model for forecasting Gleason score ≥7 in potential prostate cancer patients to reduce unnecessary prostate biopsies. Li X; Pan Y; Huang Y; Wang J; Zhang C; Wu J; Cheng G; Qin C; Hua L; Wang Z Int Urol Nephrol; 2016 Apr; 48(4):535-40. PubMed ID: 26810323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]